Innovent Biologics (01801.HK) and Spero Therapeutics (Nasdaq: SPRO) announced an exclusive license agreement for IBI355, a third-generation Fc-silent anti-CD40L antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE